Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension

Key facts

Sponsor

Zhejiang University

Principal Investigator

Junzhu Chen, MD

First Affiliated Hospital of Zhejiang University

Intervention

Transplantation of autologous endothelial progenitor cells(procedure)

Enrollment

98 enrolled

Eligibility

18-60 years · All sexes

Timeline

2005 – 2007

Study locations (1)

• Department of Cardiology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Heritable pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06850792
  imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
  University of Sao Paulo General Hospital
• ACTIVE NOT RECRUITINGNCT06587074
  Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary Hypertension When Using Modern Strategies of Specific Therapy
  Russian Cardiology Research and Production Center
• RECRUITINGNCT05462574
  Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
  Vanderbilt University Medical Center

See all trials for Heritable pulmonary arterial hypertension →